Atezolizumab (programmed cell death-ligand 1 antibody)-induced inflammation of actinic keratosis: A case report

Atezolizumab is a programmed cell death-ligand 1 antibody that modulates the immune system response and has shown great promise in treating malignancies. Cutaneous toxicities from immune checkpoint inhibitors are the most commonly reported immune-related adverse events, although toxicities related t...

Descripción completa

Detalles Bibliográficos
Autores principales: Spitz, Kathleen E, Chu, Lena, Swerlick, Robert A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
JCMS Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9661553/
https://www.ncbi.nlm.nih.gov/pubmed/36388634
http://dx.doi.org/10.1177/2050313X221131863
_version_ 1784830502518128640
author Spitz, Kathleen E
Chu, Lena
Swerlick, Robert A
author_facet Spitz, Kathleen E
Chu, Lena
Swerlick, Robert A
author_sort Spitz, Kathleen E
collection PubMed
description Atezolizumab is a programmed cell death-ligand 1 antibody that modulates the immune system response and has shown great promise in treating malignancies. Cutaneous toxicities from immune checkpoint inhibitors are the most commonly reported immune-related adverse events, although toxicities related to immunotherapy are still being characterized. Herein, we present a novel case of inflamed actinic keratoses in a patient after receiving atezolizumab therapy that resolved without requirement of dose adjustment or discontinuation of treatment.
format Online
Article
Text
id pubmed-9661553
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-96615532022-11-15 Atezolizumab (programmed cell death-ligand 1 antibody)-induced inflammation of actinic keratosis: A case report Spitz, Kathleen E Chu, Lena Swerlick, Robert A SAGE Open Med Case Rep JCMS Case Report Atezolizumab is a programmed cell death-ligand 1 antibody that modulates the immune system response and has shown great promise in treating malignancies. Cutaneous toxicities from immune checkpoint inhibitors are the most commonly reported immune-related adverse events, although toxicities related to immunotherapy are still being characterized. Herein, we present a novel case of inflamed actinic keratoses in a patient after receiving atezolizumab therapy that resolved without requirement of dose adjustment or discontinuation of treatment. SAGE Publications 2022-11-11 /pmc/articles/PMC9661553/ /pubmed/36388634 http://dx.doi.org/10.1177/2050313X221131863 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle JCMS Case Report
Spitz, Kathleen E
Chu, Lena
Swerlick, Robert A
Atezolizumab (programmed cell death-ligand 1 antibody)-induced inflammation of actinic keratosis: A case report
title Atezolizumab (programmed cell death-ligand 1 antibody)-induced inflammation of actinic keratosis: A case report
title_full Atezolizumab (programmed cell death-ligand 1 antibody)-induced inflammation of actinic keratosis: A case report
title_fullStr Atezolizumab (programmed cell death-ligand 1 antibody)-induced inflammation of actinic keratosis: A case report
title_full_unstemmed Atezolizumab (programmed cell death-ligand 1 antibody)-induced inflammation of actinic keratosis: A case report
title_short Atezolizumab (programmed cell death-ligand 1 antibody)-induced inflammation of actinic keratosis: A case report
title_sort atezolizumab (programmed cell death-ligand 1 antibody)-induced inflammation of actinic keratosis: a case report
topic JCMS Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9661553/
https://www.ncbi.nlm.nih.gov/pubmed/36388634
http://dx.doi.org/10.1177/2050313X221131863
work_keys_str_mv AT spitzkathleene atezolizumabprogrammedcelldeathligand1antibodyinducedinflammationofactinickeratosisacasereport
AT chulena atezolizumabprogrammedcelldeathligand1antibodyinducedinflammationofactinickeratosisacasereport
AT swerlickroberta atezolizumabprogrammedcelldeathligand1antibodyinducedinflammationofactinickeratosisacasereport

Ejemplares similares